REG - Nomura Holdings, Inc Takeda Pharma.Co.Ltd - Form 8 (DD) - Takeda Pharmaceutical Company Ltd

Takeda Pharmaceutical CoAnnouncement

13/07/2018 10:15

RNS Number : 5896U
Nomura Holdings, Inc
13 July 2018
 


SUPPLEMENTAL FORM 8 (SBL)
 
DETAILS OF SECURITIES BORROWING AND LENDING AND
FINANCIAL COLLATERAL ARRANGEMENTS BY
PARTIES TO AN OFFER AND PERSONS ACTING IN CONCERT
Note 5(l) on Rule 8 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION
 




Full name of person making disclosure:


Nomura Holdings Inc.




Name of offeror/offeree in relation to whose relevant securities this form relates:


Takeda Pharmaceutical Company Limited




 
 
2.         SECURITIES BORROWING AND LENDING/FINANCIAL COLLATERAL POSITIONS
 




Class of relevant security: JP3463000004


Ordinary shares




 


Number
 


%




Securities borrowed:


519,935


0.066




Securities lent (including securities subject to a security financial collateral arrangement with right of use or a title transfer collateral arrangement):


-516,147
 


-0.066




 
Details of borrowed relevant securities which have been either on-lent or sold do not need to be disclosed.
 
3.         SECURITIES BORROWING AND LENDING/FINANCIAL COLLATERAL TRANSACTIONS
 




Class of relevant security


Nature of transaction
e.g. securities lending/borrowing, delivery/receipt of recalled securities, entering into financial collateral arrangement with right of use, entering into title transfer collateral arrangement etc.


Number of securities




Ordinary


Borrow


38,646




Ordinary


Borrow (Full return)


-59,446




Ordinary


Loan


-515,747




Ordinary


Loan (Full return)


 554,393




 
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
 
http://www.rns-pdf.londonstockexchange.com/rns/5896U_1-2018-7-13.pdf
 
http://www.rns-pdf.londonstockexchange.com/rns/5896U_2-2018-7-13.pdf                      




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DCCMMGMNLFZGRZG